Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2023 · 10-Q
Revenue$407.00K$407.00K−22.3% vs Q3 2022 Net Income-$876.00K-$876.00KN/M vs Q3 2022 EPS Diluted-$0.01-$0.01no prior Q3 2022 on file Gross Profit$196,000−39.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$665,000N/M Free Cash Flowderived-$704,000N/M Margins · derivedGross margin48.2%−13.9 pt vs Q3 2022
Operating margin-215.0%−70.1 pt vs Q3 2022
Net margin-215.2%−70.2 pt vs Q3 2022
ended Apr 30, 2023 · filed Jun 14, 2023 · 45 d after period end